First-of-its-kind fentanyl vaccine attacks overdoses before they start

A vaccine to protect against the deadly effects of fentanyl is headed for human clinical trials.

The vaccine, which showed positive results in studies with mice and rats, is designed to block fentanyl from entering the brain, blocking its effects and preventing overdoses.

If approved, it would become the first treatment to prevent fentanyl overdoses, which is the leading cause of drug overdose deaths, statistics show. This is different from treatments like naloxone, which reverse the effects after an overdose.

DEADLY DRUGS MIX DRIVES SPECTACULAR INCREASE IN OVERDOSE DEATHS AMONG SENIORS

how it works

The vaccine is designed to create antibodies against fentanyl, which prevents the drug from crossing the blood-brain barrier. It contains a synthetic fragment of fentanyl linked to a protein called CRM197, along with dmLT, a compound that activates the immune system.

This combination stimulates the immune system to produce antibodies that capture fentanyl in the bloodstream before it can reach the brain, according to Colin Haile, co-founder and scientific advisor of ARMR Sciences at the University of Houston, which licensed the vaccine.

“In a vaccinated individual, those anti-fentanyl antibodies are in the blood,” Haile told News Digital. “So if they take fentanyl, the antibodies attach to the drug and prevent it from reaching the brain. They wouldn’t feel any effects if they ingested fentanyl, absolutely none. And they wouldn’t overdose.”

Over time, he said, the fentanyl would be eliminated from the body.

BIG CANNABIS STUDY FINDS LITTLE EVIDENCE FOR POPULAR MEDICAL CLAIMS, POINTS BIG DANGERS

In studies with mice and rats, the animals still had antibodies to fentanyl six months after vaccination, added Haile, who is also an associate research professor of psychology at UH and a founding member of the UH Drug Discovery Institute.

While some have questioned whether such a vaccine would indirectly encourage drug use, Haile noted that for vaccinated people, the drug “would have no euphoric effects,” so those seeking a “high” would not get it.

The main benefit, according to Haile, is that the vaccine would reduce the potential health dangers of fentanyl.

“Respiratory depression is the primary death-inducing effect of this highly potent synthetic opioid,” he said.

Aimed at trials

Following successful testing in mice and rats, the first human clinical trial is planned to begin in early 2026 at the Human Medicines Research Center, associated with Leiden University in the Netherlands.

“They wouldn’t feel any effects if they ingested fentanyl, absolutely none. And they wouldn’t overdose.”

The small phase 1 trial will enroll about 40 participants and will focus on safety and immune response.

Following the Phase 1 safety trial, a Phase 2 trial will test whether the vaccine effectively blocks the effects of fentanyl in humans.

Potential risks and limitations

The main limitation is that so far data is only available for mouse models and it is unknown how effective the vaccine would be in humans.

Haile told News Digital that no adverse side effects were reported in the animal study, likely because the vaccine ingredients are proteins that have already been used in other combinations in humans, so their safety profile is already known.

CLICK HERE FOR MORE HEALTH STORIES

“In addition, unlike other vaccines, we use extremely low doses of the components,” he noted. “We have given the vaccine to many animals and have not observed any adverse side effects.”

Even in a toxicology study, during which researchers administered 20 times the vaccine dose that would be given to humans, they saw no obvious signs of toxicity, according to Haile.

Potential use cases

Haile mentioned several different use cases for the vaccine, primarily those with opioid use disorder who want to stop using fentanyl. It could also be used by first responders and healthcare workers who want to reduce the risk of accidental exposure.

CLICK HERE TO DOWNLOAD THE News APP

Military and national security personnel could also benefit from the vaccine, Haile said, as it could help protect against fentanyl and similar compounds that have been used as chemical threats.

Lastly, parents may be seeking protection for at-risk teens or young adults, as fentanyl is known to be mixed with other substances, such as marijuana.

Looking ahead, Haile said this could pave the way for the approval of other anti-drug vaccines, such as cocaine and methamphetamine, which are already in the works.

“If we can address the main ones (fentanyl, cocaine and methamphetamine) we will be saving hundreds of thousands of lives,” he added.

“This is likely to prevent many overdoses where a patient is sedated and stops breathing as a result of the fentanyl.”

News senior medical analyst Dr. Marc Siegel said the vaccine progress is a “very exciting development with a huge upside.”

“I’m very happy that it’s now entering human trials; it’s being studied very well,” he told News Digital. “This is likely to prevent many overdoses where a patient is sedated and stops breathing as a result of the fentanyl.”

TRY OUR LATEST LIFESTYLE QUIZ

The antidote to fentanyl (Narcan) is limited because fentanyl lasts many hours, but Narcan (an opioid antagonist) wears off after only a few hours and must be re-administered, Siegel said.

“We need to make sure that this vaccine is limited to those who are really at risk for opioid overdose and addiction, because fentanyl is also a useful pain reliever for cancer and a useful agent for anesthesia,” the doctor added.

CLICK HERE TO SUBSCRIBE TO OUR HEALTH NEWSLETTER

The vaccine was developed with funding from the US Department of Defense and licensed to biotech startup ARMR Sciences.